Women's Health
Mounjaro for Women Over 40
Quick Answer: Mounjaro (tirzepatide) is an effective weight loss treatment for women over 40, including those experiencing perimenopausal and menopausal weight changes. Its dual GLP-1/GIP mechanism addresses several specific biological drivers including insulin resistance, visceral fat accumulation and amplified hunger signalling. SURMOUNT-1's mean participant age was 44 — making the data directly representative of this demographic. Average weight loss of approximately 20–22% at 15 mg over 72 weeks is achievable.22.5%avg weight loss at 15 mg (SURMOUNT-1)
44 yrsmean participant age in SURMOUNT-1
18.4 cmaverage waist reduction at 15 mg — largest of any licensed treatment
The Biology
Why Weight Loss Changes After 40 for Women
The biological environment changes substantially during perimenopause and menopause. Declining oestrogen redistributes fat to the abdomen, increases insulin resistance and lowers resting metabolic rate. Progesterone decline removes a natural appetite buffer. Sleep disruption from hot flushes elevates cortisol and hunger hormones. The result is a physiological environment where weight gain becomes almost inevitable without effective intervention.
How Each Hormone Affects Weight — and How Mounjaro Helps
| Hormone | Role | After 40 | Mounjaro's Action |
|---|---|---|---|
| Oestrogen | Fat distribution & insulin sensitivity | Drives visceral fat; reduces insulin sensitivity | GIP mechanism improves insulin sensitivity; appetite suppression reduces calorie surplus |
| Progesterone | Sleep, mood & cravings | Decline intensifies cravings, disrupts sleep | Dual GLP-1/GIP action blunts cravings via brain reward centres |
| Insulin | Blood glucose & fat storage | Worsening insulin resistance promotes fat storage | GIP receptor agonism provides additional insulin sensitisation — advantage over Wegovy |
| Leptin/Ghrelin | Fullness & hunger signals | Blunted satiety; amplified hunger drive | Dual GLP-1/GIP reinforces satiety through multiple pathways simultaneously |
Mounjaro's GIP advantage: For women over 40 with worsening insulin resistance, Mounjaro's additional GIP receptor activity provides insulin sensitisation beyond what semaglutide (Wegovy) achieves — making it particularly well-matched to the metabolic challenges of this life stage.
Expected Results
Weight Loss Timeline for Women Over 40
Safety Considerations for Women Over 40
| Timepoint | Expected Weight Loss | Key Changes |
|---|---|---|
| Month 1–2 | 1–4 kg (1–4%) | Appetite begins to reduce; energy may dip initially |
| Month 3 | 7–9% | Noticeable weight loss; abdominal changes often visible |
| Month 6 | ~13–16% | Significant visceral fat reduction; metabolic markers improving |
| Month 12 | ~20–22% | Full treatment effect; blood pressure and metabolic health sustained |
| Consideration | Detail | Action |
|---|---|---|
| Bone density | Rapid weight loss can reduce bone mineral density; elevated risk post-menopause | Weight-bearing exercise and adequate calcium/vitamin D |
| HRT interaction | No known pharmacokinetic interaction between tirzepatide and HRT | Inform prescriber of all HRT medications |
| Gallbladder risk | Weight loss increases gallstone risk in women | Report upper right abdominal pain promptly |
| Contraception | Mounjaro may affect contraceptive pill absorption — use additional contraception for 4 weeks after each dose increase | Discuss with prescriber |
FAQs
Frequently Asked Questions
Yes. SURMOUNT-1's mean participant age was 44 and the trial was majority female, making its data directly representative. Mounjaro produces approximately 22.5% average weight loss at 15 mg over 72 weeks. Its dual GIP mechanism provides insulin sensitisation that is particularly relevant for women whose insulin resistance is worsening with age.
Mounjaro's GIP receptor activity provides insulin sensitisation beyond what semaglutide achieves — directly addressing the accelerating insulin resistance of the menopausal transition. The superior visceral fat reduction (average 18.4 cm waist circumference vs 13.5 cm for Wegovy) is particularly significant for menopausal women.
Yes — there is no known pharmacokinetic interaction between tirzepatide and HRT. Women currently taking HRT who meet Mounjaro's eligibility criteria can be prescribed both concurrently, subject to clinical assessment. Inform your prescribing pharmacist of all HRT medications.
Yes. SURMOUNT-1 data shows average waist circumference reductions of 18.4 cm at 15 mg — the largest of any licensed weight management treatment. For menopausal women, visceral fat reduction is particularly important given its independent association with cardiovascular and metabolic risk.
Women in active perimenopause may find their weight loss trajectory is slightly less linear, with plateaus corresponding to hormonal shifts — this is normal. However, perimenopause does not prevent meaningful weight loss. The SURMOUNT-1 majority-female population with mean age 44 represents this group directly.
Rapid weight loss can reduce bone mineral density, which is a relevant consideration for post-menopausal women. Maintaining adequate calcium and vitamin D and incorporating weight-bearing and resistance exercise throughout treatment is strongly recommended.
Ready to Start Mounjaro Treatment?
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment
Check Your Eligibility →
Jastreboff AM et al. SURMOUNT-1. N Engl J Med. 2022. Tcernof A, Despres JP. Physiol Rev. 2013. NICE TA1026. 2024. Happy Pharmacy (GPhC No. 9012585). Educational purposes only.